Cytisine for Smoking Cessation
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 20 people enrolled
- Started
- 8 Feb 2023
- Ended
- 12 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cytisine
- Placebo
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Aged 18-65 years
- Have TUD assessed by structured clinical interview for DSM-5
- Have past year AUD (active) assessed by structured clinical interview for DSM-5
- Report daily cigarette consumption in past month and expired carbon monoxide (CO) measurement ≥10ppm at screening
- Have Fagerstrom Test of Nicotine Dependence (FTND55) score ≥4
- Have motivation to quit within 30 days i.e. Contemplation Ladder56 score ≥7
- Be willing and able to comply with all study procedural and assessment demands
- Be able to provide voluntary written informed consent
Who cannot take part
- Have a serious unstable psychiatric or medical condition preventing participation in the trial. This includes some forms of schizophrenia, ischemic heart disease, heart failure, arterial hypertension (systolic BP above 150; diastolic BP above 100), cerebrovascular diseases, occlusion of blood vessels, kidney and/or liver disease, hyperthyroidism, ulcer, diabetes, Chromaffin tumours of the adrenal medulla, and gastroesophageal reflux disease (GERD)
- Report prolonged smoking abstinence in the past month preceding screening
- Be using other smoking cessation aids
- Enrolled in another smoking cessation program
- Be pregnant, breastfeeding, or intending to become pregnant or breastfeed
- Exhibit suicidal thoughts or behavior in the past month
- Enrolled in another study which would interfere with study procedures or represent a potential risk to the participant
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the safety and effectiveness of cytisine as a smoking cessation treatment in individuals with concurrent alcohol use disorder.
The 2 groups in the trial
- CytisineTreatment being tested
Cytisine will be given as 1.5 mg tablet formulations for 25 days. The following treatment schedule will be followed: * Days 1 to 3: 1.5 mg taken every 2 hours (6 pills (9 mg)/day) * Days 4 to 12: 1.5 mg taken every 2.5 hours (5 pills (7.5 mg)/day) * Days 13 to 16: 1.5 mg taken every 3 hours (4 pills (6 mg)/day) * Days 17 to 20: Taper down to 1 tablet every 5 hours (3 pills (4.5 mg)/day) * Days 21 to 25: Taper down to 1-2 tablets daily (1.5-3 mg/day)
- PlaceboPlacebo, for comparison
Placebo will be given following the same schedule as the Cytisine Arm.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cytisine: Testing Its Potential as a Therapeutic Strategy for Smoking Cessation Among People With Concurrent Alcohol Use Disorder
- Record updated
- 27 February 2026